Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | GLA | P06280 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27723070 | 0.98 | LMNA (0.44) | LMNATSHRPOLBALDH1A1RAB9A | |
| Propionic Acid SCHEMBL10343203 | 0.93 | ALDH1A1 (0.41) | LMNATSHRPOLBALDH1A1RAB9A | |
| SCHEMBL8526268 | 0.89 | RAB9A (0.46) | LMNATSHRPOLBALDH1A1RAB9A | |
| SCHEMBL1194369 | 0.88 | TSHR (0.46) | LMNATSHRPOLBALDH1A1RAB9A | |
| SCHEMBL324052 | 0.86 | LMNA (0.47) | LMNAPOLBALDH1A1RAB9AL3MBTL1 | |
| SCHEMBL323833 | 0.86 | LMNA (0.47) | LMNAPOLBALDH1A1RAB9AL3MBTL1 | |
| SCHEMBL324921 | 0.86 | LMNA (0.47) | LMNAPOLBALDH1A1RAB9AL3MBTL1 | |
| SCHEMBL11650239 | 0.86 | LMNA (0.47) | LMNAPOLBALDH1A1RAB9AL3MBTL1 | |
| SCHEMBL21603056 | 0.86 | LMNA (0.47) | LMNAPOLBALDH1A1RAB9AL3MBTL1 | |
| SCHEMBL7158840 | 0.86 | LMNA (0.47) | LMNAPOLBALDH1A1RAB9AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1637141-B1 | Stabilized protease composition comprising a serine protease, morpholino derivatives and reversible inhibitors of said serine protease | TROBIO AB (SE) | 2011-11-16 | — | — | EP | claimed |
| WO-2011131234-A1 | SENSOR APPARATUS ADAPTED TO BE INCORPORATED IN A GARMENT | WEARABLE INFORMATION TECHNOLOGIES, S.L. (WEARTECH) (ES) | 2011-10-27 | — | — | WO | claimed |
| US-20090136474-A1 | Stabilized Protease Composition | TROBIO AB (SE) | 2009-05-28 | — | — | US | claimed |
| WO-2007035143-A1 | STABILIZED PROTEASE COMPOSITION | TROBIO AB (SE) | 2007-03-29 | — | — | WO | claimed |
| EP-1637141-A1 | Stabilized protease composition comprising a serine protease, morpholino derivatives and reversible inhibitors of said serine protease | Trobio AB (SE) | 2006-03-22 | — | — | EP | claimed |
| CN-113321269-A | Method for effectively separating organic matters in high-salinity wastewater | 中国科学院过程工程研究所 | 2021-08-31 | — | — | CN | disclosed |
| CN-104622809-B | The drug of modification for elaioplast nanometer particle | 英属哥伦比亚大学 | 2019-04-19 | — | — | CN | disclosed |
| CN-106132972-A | For treating the novel amino phosphate ester of HCV infection | 银杏树药业(苏州)有限公司 | 2016-11-16 | — | — | CN | disclosed |
| CN-102105135-B | Modified drugs for liposomal nanoparticles | 英属哥伦比亚大学 | 2016-08-24 | — | — | CN | disclosed |
| CN-104622809-A | Modified drugs for use in liposomal nanoparticles | UNIV BRITISH COLUMBIA | 2015-05-20 | — | — | CN | disclosed |
| US-8574569-B2 | Stabilized protease composition | TROBIO AB (SE) | 2013-11-05 | — | — | US | disclosed |
| US-20130157339-A1 | STABILIZED PROTEASE COMPOSITION | TROBIO AB (SE) | 2013-06-20 | — | — | US | disclosed |
| CN-102105135-A | Modified drugs for liposomal nanoparticles | UNIV BRITISH COLUMBIA | 2011-06-22 | — | — | CN | disclosed |
| CN-101528846-A | Inorganic-organic hybrid composition and use thereof | NOF CORP (JP) | 2009-09-09 | — | — | CN | disclosed |
| US-20090136474-A1 | Stabilized Protease Composition | TROBIO AB (SE) | 2009-05-28 | — | — | US | disclosed |
| CN-101384586-A | PI-3 kinase inhibitors and methods of use thereof | NOVARTIS AG (CH) | 2009-03-11 | — | — | CN | disclosed |
| WO-2007035143-A1 | STABILIZED PROTEASE COMPOSITION | TROBIO AB (SE) | 2007-03-29 | — | — | WO | disclosed |
| EP-1637141-A1 | Stabilized protease composition comprising a serine protease, morpholino derivatives and reversible inhibitors of said serine protease | Trobio AB (SE) | 2006-03-22 | — | — | EP | disclosed |
| CN-1299348-A | sPLA for treatment of disease2Inhibitor compounds | LILLY CO ELI (US) | 2001-06-13 | — | — | CN | disclosed |
| CN-1131420-A | Anhydrous crystalline MYCOPHENOLATE 2- (4-morpholino) ethyl ester (MYCOPHENOLATE MOFETIL) and intravenous formulations thereof | SYNTEX S A INC (US) | 1996-09-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090136474-A1 | Stabilized Protease Composition | SERPINE1, SERPINB1, CTRL | LMNA 505/4885TSHR 4487/4885POLB 3135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.